Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Table 6 Impact of various independent variables on achieving pCR

Variable	Univariate analysis		Multivariate analysis
Variable	P value	OR (95% CI)	P value	OR (95% CI)
Primary tumor size	0.083	1.032 (0.996–1.07)	0.241	01.031 (0.98–1.085)
High tumor grade (III)	0.049	3.75 (1.003–14.02)	0.025	0.015 (0.0–0.585)
HER2 positivity	0.007	0.171 (0.48–0.617)	0.02	0.055 (0.005–0.636)
Ki67 positivity	0.037	0.179 (0.035–0.903)	0.018	0.028 (0.001–0.548)
TILs	0.022	0.227 (0.064–0.80)	0.015	0.058 (0.006–0.58)
NACT (Carboplatin+Gemcitabine)	0.853	0.895 (0.275–2.91)	0.518	1.94 (0.26–14.46)
Molecular subtype
HR+/HER2+	0.005	0.045 (0.005–0.399)	0.026	0.048 (0.003–0.69)
HR−/HER2+	0.218	0.149 (0.007–3.078)	0.368	0.158 (0.003–8.831)
HR−/HER2-	0.036	0.050 (0.003–0.824)	0.452	0.244 (0.006–9.628)

NACT Neoadjuvant chemotherapy, TIL Tumor-infiltrating lymphocytes, HR Hormone receptor, OR Odd Ratio, CI Confidence Interval

ISSN: 1471-2407